Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- BUSINESS NEWS IN BRIEF
October 19, 2009
- Pharmacists Should Play Key Role in Promoting Use of Generics: JSGM Seminar
October 19, 2009
- Discussions on Medical Fees Halted
October 19, 2009
- Korosho Urges Nat'l Univ. Hospitals to Use More Generics
October 19, 2009
- Industry Should Show Evidence of Pressure on Profits due to Drug Price Curtailment: JMARI
October 19, 2009
- 2012 IGPA Annual Conference to Be Held in Japan
October 19, 2009
- Budget to Support Development of Unapproved Drugs, Indications Cut to ¥10 Bil.
October 19, 2009
- HSTTC Licenses Tumor Markers to TransGenic
October 19, 2009
- Korosho's Supplementary Budget Cut by ¥435.9 Bil.
October 19, 2009
- TOPICS 2 articles
October 19, 2009
- Korosho to Reshuffle CDFS's 1st, 2nd Committees on Drugs Next April
October 19, 2009
- Erbitux's Efficacy Correlated with KRAS Gene Mutation in Japanese Patients as Well
October 19, 2009
- REGULATORY NEWS IN BRIEF
October 12, 2009
- Mediceo to Further Cut Distribution Costs
October 12, 2009
- Astellas Concentrates Drug Discovery Functions in Tsukuba
October 12, 2009
- Eisai Ties Up with DNDi for Chagas Disease
October 12, 2009
- New Antibody Drugs for Cancer Highlighted at JCA Annual Meeting
October 12, 2009
- Korosho to Support Development of 12 Unapproved Drugs
October 12, 2009
- MEDICAL DEVICE NEWS IN BRIEF
October 12, 2009
- R&D NEWS IN BRIEF
October 12, 2009
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…